COMP <GO>
SIBN vs SGP // EV/EBITDA & P/E VALUATION
SI-BONE Inc. (NASDAQ) VS. SpyGlass Pharma Inc. (NASDAQ) • 15-METRIC TALLY: SIBN 3
— SGP 2
■ METRIC PARITY
LAST: $22.41 (+2.66%) • MKT CAP: $1.00B
valuation
—
LAST: $32.51 (-1.06%) • MKT CAP: $1.09B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIBN VS. SGP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SIBN | SGP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.30% | -35.00% | +24.70 | SIBN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.90% | -3.08% | +2.18 | SIBN | /fcf-yield <GO> |
| Operating Margin | -11.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -9.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.73 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 2/9 | +4.00 | SIBN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 71.4 | -12.74 | SGP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.00B | $1.09B | -$83.0M | SGP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SIBN REV | SGP REV | SIBN GROSS % | SGP GROSS % | SIBN FCF | SGP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $200.9M | $0 | 79.6% | — | -$9.1M | -$33.5M |
| FY 2024 | $167.2M | $0 | 79.0% | — | -$22.9M | -$24.0M |
| FY 2023 | $138.9M | — | — | — | -$18.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIBN // BETA —
SGP // BETA —